Literature DB >> 498422

DNA-binding parameters of daunorubicin and doxorubicin in the conditions used for studying the interaction of anthracycline-DNA complexes with cells in vitro.

Y J Schneider, R Baurain, A Zenebergh, A Trouet.   

Abstract

Affinity constants of daunorubicin and doxorubicin for DNA at 37 degrees C and in presence of 10% serum were determined by an optical method and calculated from Scatchard plots. Values from 0.10 to 0.12 and from 0.13 to 0.16 X 10(6) M-1 were obtained for daunorubicin and doxorubicin, respectively. According to these affinity constants, the amounts of free drugs were calculated for various concentrations of daunorubicin-DNA or doxorubicin-DNA and for various molar ratios. In a large range of concentrations there is rather stable concentration of both free drugs, and these concentrations are inversely proportional to the nucleotides/drug ratio. The amount of free drug present in the medium is low as long as the concentration of daunorubicin-DNA or doxorubicin-DNA is higher than 1 microgram/ml (expressed as drug concentration). At lower concentrations, however, the percentage of free drug increases very sharply.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 498422     DOI: 10.1007/bf00253097

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  Thermodynamics of the interaction of daunomycin with DNA.

Authors:  Y M Huang; D R Phillips
Journal:  Biophys Chem       Date:  1977-04       Impact factor: 2.352

2.  Experimental leukemia chemotherapy with a "lysosomotropic" adriamycin-DNA complex.

Authors:  A Trouet; D Deprez-de Campeneere; M de Smedt-Malengreaux; G Atassi
Journal:  Eur J Cancer       Date:  1974-07       Impact factor: 9.162

3.  Chemotherapy through lysosomes with a DNA-daunorubicin complex.

Authors:  A Trouet; D Deprez-de Campeneere; C De Duve
Journal:  Nat New Biol       Date:  1972-09-27

4.  Uptake and subcellular localization of daunorubicin and adriamycin in cultured fibroblasts.

Authors:  G Noel; C Peterson; A Trouet; P Tulkens
Journal:  Eur J Cancer       Date:  1978-04       Impact factor: 9.162

5.  Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex.

Authors:  M Beran; B Andersson; S Eksborg; H Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

6.  Uptake of the daunorubicin-DNA complex in cultured fibroblasts.

Authors:  C Peterson; G Noël; A Zenebergh; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

7.  Comparative study in mice of the toxicity, pharmacology, and therapeutic activity of daunorubicin-DNA and doxorubicin-DNA complexes.

Authors:  D Deprez-De Campeneere; R Baurain; M Huybrechts; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

8.  Adriamycin and adriamycin--DNA in inoperable bronchogenic carcinoma. A randomized study with cyclophosphamide vinblastine.

Authors:  A Bosly; J Prignot; C Ledent; G Sokal; A Trouet
Journal:  Eur J Cancer       Date:  1978-06       Impact factor: 9.162

9.  Cytostatic efficacy of DNA-complexes of adriamycin, daunomycin and actinomycin D. I. Comparative studies in Novikoff hepatoma, human mammary carcinoma cells and human leukemic leukocytes.

Authors:  S Seeber; K P Brucksch; B Seeber; C G Schmidt
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1977-05-20

10.  Clinical trials with daunorubicin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute nonlymphoblastic leukemia, and bronchogenic carcinoma.

Authors:  A Ferrant; R Hulhoven; A Bosly; G Cornu; J L Michaux; G Sokal
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

  10 in total
  12 in total

1.  Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia.

Authors:  C Paul; M Björkholm; I Christenson; L Engstedt; G Gahrton; R Hast; G Holm; A Killander; B Lantz; D Lockner; B Lönnqvist; H Mellstedt; J Palmblad; C Peterson; B Simonsson; A M Stalfelt; A M Udén; B Wadman; G Oberg
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

2.  Cellular pharmacokinetics of daunorubicin: uptake by leukaemic cells in vivo and fate.

Authors:  V Trillet; M Lakhal; J Lang; E Perrin-Fayolle; Q Timour Chah; D Fière; G Faucon
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.

Authors:  A Zenebergh; R Baurain; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 4.  Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.

Authors:  V Ashutosh Rao
Journal:  Antioxid Redox Signal       Date:  2012-10-26       Impact factor: 8.401

5.  Daunorubicin-DNA and doxorubicin-DNA. A review of experimental and clinical data.

Authors:  A Trouet; D Deprez-De Campeneere
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

6.  Cytofluorescence localization of adriamycin in resistant colon cancer cells.

Authors:  B Chauffert; F Martin; A Caignard; J F Jeannin; A Leclerc
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Plasma levels of doxorubicin after IV bolus injection and infusion of the doxorubicin-DNA complex in rabbits and man. Comparison with free doxorubicin.

Authors:  R Baurain; D Deprez-De Campeneere; A Zenebergh; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice.

Authors:  H M Yang; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

9.  Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization.

Authors:  Allan D Heibein; Baoqing Guo; Jason A Sprowl; David A Maclean; Amadeo M Parissenti
Journal:  BMC Cancer       Date:  2012-08-31       Impact factor: 4.430

10.  Importance of intracellular pH in determining the uptake and efficacy of the weakly basic chemotherapeutic drug, doxorubicin.

Authors:  Pawel Swietach; Alzbeta Hulikova; Shalini Patiar; Richard D Vaughan-Jones; Adrian L Harris
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.